Gene therapy to modify pulmonary host defenses.
Gene therapy to modify pulmonary host defenses.
复制标题
改变肺部宿主防御的基因疗法。
DOI：
10.1053/srin.2001.22725
复制
发表时间：
2001
期刊：
影响因子：
--
通讯作者：
Shellito,JE
中科院分区：
文献类型：
--
作者：
Kolls,JK;Ye,P;Shellito,JE
呼吸道感染仍然是一个重要的公共卫生问题，目前是美国第六大死亡原因。在社区获得性感染和医院感染中，抗生素耐药微生物越来越多。尽管在抗生素开发方面取得了进展，但生物反应调节剂可能越来越多地应用于增强肺部宿主对耐药感染或高危宿主的防御。为此，基因治疗提出以核酸而不是蛋白质的形式递送生物制剂。基因治疗具有将生物靶向特定细胞或组织区室的潜在优势，以及更有利的药代动力学特征。在肺部感染的临床前模型的基因传递和疗效的数据进行了介绍和讨论。
Respiratory infections remain a significant public health problem and are presently the 6th leading cause of death in the United States. Antibiotic-resistant organisms are encountered increasingly in both community-acquired and nosocomial infections. Despite progress in antibiotic development, biological-response modifiers may have increasing application to augment pulmonary host defenses against either drug-resistant infections or in high-risk hosts. Toward this end, gene therapy proposes to deliver biologicals as nucleic acids rather than protein. Gene therapy has the potential advantage of targeting the biological to specific cells or tissue compartments, and a more favorable pharmacokinetic profile. Data on gene delivery and efficacy in preclinical models of pulmonary infection are presented and discussed.